NDAORALTABLET
Approved
Mar 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CENESTIN (estrogens, conjugated synthetic a) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. First approved in 1999.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CENESTIN is a synthetic conjugated estrogen oral tablet indicated for hormone replacement therapy in postmenopausal women. It works by binding to nuclear estrogen receptors in target tissues to replace declining endogenous estrogen levels. The drug addresses vasomotor symptoms and other menopausal manifestations through receptor-mediated mechanisms similar to natural estrogen metabolism.
LOE Approaching
Product approaching loss of exclusivity with high competitive pressure (30/100) signals a contracting commercial footprint and potential team restructuring.
Mechanism of Action
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on CENESTIN at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.